<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00550498</url>
  </required_header>
  <id_info>
    <org_study_id>3086</org_study_id>
    <nct_id>NCT00550498</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplantation in Ocular Lesions of Behcet's Disease</brief_title>
  <official_title>Phase 1 Study of Bone Marrow - Derived Stem Cell in the Treatment of Ocular Lesions of Behcet's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find if autologous stem cell transplantation can stop the
      progression of intractable eye lesions of Behcet's Disease or even to improve it.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To test in a pilot study the effect of autologous stem cell transplantation in stopping the
      progression of retinal damage of eye lesions in Behcet's Disease by repairing the vascular
      damage, and possibly to improve the lesions.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No improvement obtained in 3 cases. Retinal detachment observed in 2 cases
  </why_stopped>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1- Visual acuity by ETDRS (Early Treatment of Diabetic Retinopathy Study). 2- Retinal state and retinal edema by Color Photography, Multifocal Electroretinography, and OCT (Optic Coherent Tomography).</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Retinitis</condition>
  <condition>Behcet's Syndrome</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Behcet's Disease with ocular lesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Stem Cell Transplantation</intervention_name>
    <description>Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6Ã—106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 3-5 million cells, in a maximum volume of 0.3 ml. Cells will be injected in vitreal at 3.5 millimeter of limbus with a 26 gauge insulin needle.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Behcet's Disease

          -  Fulfilling the International Criteria for behcet's Disease (ICBD)

          -  Ocular lesions with retinal vasculitis

          -  Resistant to at least 3 months of combination therapy with pulse cyclophosphamide
             (1g/monthly), azathioprine (3 mg/kg/daily), and prednisolone 0.5 mg/kg/daily

          -  Visual acuity not less than 4 meters finger count

          -  Retinal edema confirmed by color photography and OCT

        Exclusion Criteria:

          -  No Vision

          -  Active posterior uveitis

          -  Fundus not visible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fereydoun Davatchi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rheumatology Research Center, Medical Sciences/University of Teheran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hormoz Shams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheumatology Research Center, Medical Sciences/University of Tehran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Behrouz Nikbin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Immunology, Medical Sciences/University of Tehran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology Research Center, Behcet's Disease Unit (Shariati Hospital)</name>
      <address>
        <city>Tehran</city>
        <zip>14114</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Otani A, Dorrell MI, Kinder K, Moreno SK, Nusinowitz S, Banin E, Heckenlively J, Friedlander M. Rescue of retinal degeneration by intravitreally injected adult bone marrow-derived lineage-negative hematopoietic stem cells. J Clin Invest. 2004 Sep;114(6):765-74.</citation>
    <PMID>15372100</PMID>
  </reference>
  <reference>
    <citation>Kicic A, Shen WY, Wilson AS, Constable IJ, Robertson T, Rakoczy PE. Differentiation of marrow stromal cells into photoreceptors in the rat eye. J Neurosci. 2003 Aug 27;23(21):7742-9.</citation>
    <PMID>12944502</PMID>
  </reference>
  <reference>
    <citation>Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002 Jul 4;418(6893):41-9. Epub 2002 Jun 20. Erratum in: Nature. 2007 Jun 14;447(7146):879-80.</citation>
    <PMID>12077603</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2007</study_first_submitted>
  <study_first_submitted_qc>October 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <last_update_submitted>November 9, 2015</last_update_submitted>
  <last_update_submitted_qc>November 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinal Vasculitis</keyword>
  <keyword>Retinal Edema</keyword>
  <keyword>Behcet's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Behcet Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

